此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety and Efficacy of MORA Cure LBP in Patients With Chronic Low Back Pain (MORACureLBP)

2026年6月17日 更新者:EverEx Inc.

A Prospective, Randomized, Open-label, Multicenter, Controlled, Comparative, Confirmatory Trial of MORA Cure in Patients With Chronic Low Back Pain: 8-week Evaluation and 12-week Follow-up

This is a prospective, randomized, open-label, multicenter, controlled, comparative, confirmatory clinical trial to evaluate the safety and efficacy of MORA Cure LBP, a multidisciplinary digital therapeutic, in patients with chronic low back pain.

Eligible participants will be randomized in a 1:1 ratio to either the experimental group using MORA Cure LBP or the control group receiving exercise education and self-exercise materials. The treatment period is 8 weeks, followed by a 4-week observation period, for a total study period of 12 weeks from baseline. The primary efficacy endpoint is usual low back pain intensity during the past week measured by the 11-point Numeric Pain Rating Scale at Week 8.

研究概览

详细说明

MORA Cure LBP is a software-based digital therapeutic intended to improve symptoms in patients with chronic low back pain by providing app-based exercise therapy and cognitive behavioral therapy. The investigational medical device consists of a patient mobile application and a clinician web program. Through the clinician web program, investigators can prescribe rehabilitation programs and monitor participants.

Participants assigned to the experimental group will use MORA Cure LBP for 8 weeks. Use of the device at least 3 times per week is recommended. After the 8-week treatment period, participants may continue to use available content during the follow-up observation period through Week 12.

Participants assigned to the control group will receive disease education, self-exercise education, and self-exercise materials. They will perform self-exercise and record exercise performance in a self-exercise diary.

Participants will attend 3 to 5 visits, including screening, baseline, Week 4, Week 8, and Week 12. The Week 4 visit may be conducted as a televisit. The Week 8 visit is the primary evaluation time point, and the Week 12 visit is the follow-up evaluation time point.

研究类型

介入性

注册 (估计的)

156

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Gyeonggi-do
      • Guri-si、Gyeonggi-do、韩国
        • Hanyang University Guri Hospital
      • Gwangmyeong、Gyeonggi-do、韩国
        • Chung-Ang University Gwangmyeong Hospital
      • Uijeongbu-si、Gyeonggi-do、韩国
        • The Catholic University of Korea Uijeongbu St. Mary's Hospital
    • Korea
      • Seoul、Korea、韩国
        • Seoul National University Hospital
    • Seoul
      • Seoul、Seoul、韩国
        • Samsung Medical Center
      • Seoul、Seoul、韩国
        • Kangbuk Samsung Hospital
      • Seoul、Seoul、韩国
        • Nowon Eulji University Hospital
      • Seoul、Seoul、韩国
        • Seoul Asan Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria

  • Adults aged 19 years or older.
  • Participants with low back pain lasting for at least 12 weeks.
  • Participants with average low back pain intensity of 4 or higher on the Numeric Pain Rating Scale.
  • Participants who are able to undergo application-based treatment using a smartphone.
  • Participants who voluntarily decide to participate in the clinical trial and sign the informed consent form before the start of the trial.
  • Participants who, in the opinion of the principal investigator, are able to comply with the clinical investigation plan.

Exclusion Criteria

  • History of previous spinal surgery.
  • History of spinal injection treatment within 1 month before screening.
  • History of spinal trauma within 3 months before screening.
  • Lower limb muscle strength of 3 or less on manual muscle testing, or lower limb radiating pain accompanied by motor dysfunction.
  • Grade 2 or higher spondylolisthesis on radiographic imaging.
  • Scoliosis, defined as Cobb angle of 25 degrees or greater with a clear structural cause based on the principal investigator's judgment, or kyphosis, defined as lumbar lordosis angle less than 0 degrees.
  • Red flag signs, such as paralysis symptoms including bladder or bowel dysfunction, or sudden unexplained weight loss.
  • Tumor, infection, metabolic bone disease, cognitive impairment, fibromyalgia, systemic inflammatory disease, or systemic inflammatory disorder.
  • Any other systemic or psychiatric condition that, in the opinion of the principal investigator, limits exercise therapy.
  • Current use of opioid analgesics with potency equal to or greater than morphine for any other disease or low back pain, such as oxycodone, fentanyl, or pethidine. Participants may participate after a 14-day washout period if applicable.
  • Pregnant participants, participants planning pregnancy during the clinical trial, or participants unable to maintain contraception during the clinical trial.
  • Current participation in another clinical trial or planned participation in another clinical trial during this study.
  • Inability to communicate, difficulty following instructions, or any other condition that, in the opinion of the principal investigator, makes the participant unsuitable for this clinical trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:MORA Cure Digital Therapeutic
Participants assigned to the experimental group will use MORA Cure, a software-based digital therapeutic consisting of a patient mobile application and clinician web program. MORA Cure provides an 8-week app-based rehabilitation exercise program and cognitive behavioral therapy for chronic low back pain. Participants are recommended to use the device at least 3 times per week. After the 8-week treatment period, participants may use available content during the observation period through Week 12.
MORA Cure is a digital therapeutic software intended to improve symptoms in patients with chronic low back pain by providing exercise therapy and cognitive behavioral therapy through a patient mobile application and clinician web program.
其他名称:
  • ETH-02K; ETH-02KW
有源比较器:Exercise Education and Self-Exercise
Participants assigned to the control group will receive disease education, exercise education, and self-exercise materials. Participants will perform self-exercise and record exercise performance in a self-exercise diary.
Participants will receive education regarding chronic low back pain and self-exercise based on the control group exercise education materials. Participants will perform self-exercise and record exercise performance in a self-exercise diary.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Usual Low Back Pain Intensity at Weeks 4 and 12 Measured by the 11-point Numeric Pain Rating Scale
大体时间:Week 4 and Week 12 after baseline
Usual low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups. The 11-point Numeric Pain Rating Scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain intensity.
Week 4 and Week 12 after baseline

次要结果测量

结果测量
措施说明
大体时间
Worst Low Back Pain Intensity at Weeks 4, 8, and 12 Measured by the 11-point Numeric Pain Rating Scale
大体时间:Week 4, Week 8, and Week 12 after baseline
Worst low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups. The 11-point Numeric Pain Rating Scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain intensity.
Week 4, Week 8, and Week 12 after baseline
Worst low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups. The 11-point Numeric Pain Rating Scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the wor
大体时间:Week 4, Week 8, and Week 12 after baseline
Worst low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups.
Week 4, Week 8, and Week 12 after baseline
Functional Disability at Weeks 4, 8, and 12 Measured by the Oswestry Disability Index
大体时间:Week 4, Week 8, and Week 12 after baseline
Functional disability related to low back pain will be assessed using the Oswestry Disability Index and compared between groups. The Oswestry Disability Index score ranges from 0 to 100, with higher scores indicating greater disability.
Week 4, Week 8, and Week 12 after baseline
Health-related Quality of Life at Weeks 4, 8, and 12 Measured by EQ-5D-5L
大体时间:Week 4, Week 8, and Week 12 after baseline
Health-related quality of life will be assessed using EQ-5D-5L and compared between groups. The EQ-5D-5L descriptive system includes 5 dimensions, each scored from 1 to 5. The total descriptive score ranges from 5 to 25, with higher scores indicating more problems and worse health-related quality of life. The EQ visual analogue scale ranges from 0 to 100, with higher scores indicating better self-rated health status.
Week 4, Week 8, and Week 12 after baseline
Change From Baseline in Usual Low Back Pain Intensity Measured by the 11-point Numeric Pain Rating Scale
大体时间:Baseline to Week 4, Week 8, and Week 12
Change from baseline in usual low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups. The 11-point Numeric Pain Rating Scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain intensity. A negative change from baseline indicates improvement.
Baseline to Week 4, Week 8, and Week 12
Change From Baseline in Worst Low Back Pain Intensity Measured by the 11-point Numeric Pain Rating Scale
大体时间:Baseline to Week 4, Week 8, and Week 12
Change from baseline in worst low back pain intensity during the past 1 week will be assessed using the 11-point Numeric Pain Rating Scale and compared between groups. The 11-point Numeric Pain Rating Scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain intensity. A negative change from baseline indicates improvement.
Baseline to Week 4, Week 8, and Week 12
Change From Baseline in Functional Disability Measured by the Oswestry Disability Index
大体时间:Baseline to Week 4, Week 8, and Week 12
Change from baseline in functional disability related to low back pain will be assessed using the Oswestry Disability Index and compared between groups. The Oswestry Disability Index score ranges from 0 to 100, with higher scores indicating greater disability. A negative change from baseline indicates improvement.
Baseline to Week 4, Week 8, and Week 12
Change From Baseline in Health-related Quality of Life Measured by EQ-5D-5L
大体时间:Baseline to Week 4, Week 8, and Week 12
Change from baseline in health-related quality of life will be assessed using EQ-5D-5L and compared between groups. The EQ-5D-5L descriptive system includes 5 dimensions, each scored from 1 to 5. The total descriptive score ranges from 5 to 25, with higher scores indicating more problems and worse health-related quality of life. The EQ visual analogue scale ranges from 0 to 100, with higher scores indicating better self-rated health status.
Baseline to Week 4, Week 8, and Week 12

其他结果措施

结果测量
措施说明
大体时间
Treatment Compliance Percentage at Weeks 4 and 8
大体时间:Week 4 and Week 8 after baseline
Treatment compliance will be assessed as a percentage and compared between the MORA Cure group and the control group. In the MORA Cure group, compliance will be assessed using data from the clinician web program. In the control group, compliance will be assessed using the self-exercise diary. Compliance ranges from 0% to 100%, with higher percentages indicating better treatment compliance.
Week 4 and Week 8 after baseline
Psychological Status at Weeks 8 and 12 Measured by the Patient Health Questionnaire-9
大体时间:Week 8 and Week 12 after baseline
Depression symptoms will be assessed using the Patient Health Questionnaire-9 and compared between groups. The Patient Health Questionnaire-9 score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.
Week 8 and Week 12 after baseline
Pain Catastrophizing at Weeks 8 and 12 Measured by the Pain Catastrophizing Scale
大体时间:Week 8 and Week 12 after baseline
Pain catastrophizing will be assessed using the Pain Catastrophizing Scale and compared between groups. The Pain Catastrophizing Scale score ranges from 0 to 52, with higher scores indicating greater pain catastrophizing.
Week 8 and Week 12 after baseline
Spinal Muscle Endurance Duration at Weeks 8 and 12 Measured by the Prone Bridge Test
大体时间:Week 8 and Week 12 after baseline
Spinal muscle endurance will be assessed using the prone bridge test and compared between groups. The outcome will be measured as the duration that the participant can maintain the prone bridge position, recorded in seconds. Higher values indicate better spinal muscle endurance.
Week 8 and Week 12 after baseline
Radiographic Spinal Alignment Parameters at Week 8 Measured by Whole-spine Lateral X-ray
大体时间:Week 8 after baseline
Radiographic spinal alignment will be assessed using whole-spine lateral X-ray and compared between groups. The parameters include lumbar lordosis, pelvic tilt, pelvic incidence, sacral slope, and sagittal vertical axis. Angular parameters will be measured in degrees, and sagittal vertical axis will be measured in millimeters.
Week 8 after baseline
Incidence of Adverse Events
大体时间:From informed consent through Week 12 and applicable safety follow-up period
Adverse events, adverse device effects, serious adverse events, and serious adverse device effects will be collected and summarized by treatment group. For adverse device effects, follow-up will be performed as applicable until 14 days after the last use of the investigational medical device.
From informed consent through Week 12 and applicable safety follow-up period

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Cho Jae Hwan, MD, PhD、Asan Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月19日

初级完成 (估计的)

2026年8月20日

研究完成 (估计的)

2026年9月30日

研究注册日期

首次提交

2026年6月11日

首先提交符合 QC 标准的

2026年6月17日

首次发布 (实际的)

2026年6月24日

研究记录更新

最后更新发布 (实际的)

2026年6月24日

上次提交的符合 QC 标准的更新

2026年6月17日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅